1. Чиссов В.И., Старинский В.В., Петрова Г.В. Злокачественные новообразования в России в 2007 году. М., 2008.
2. Parkin DM, Bray F, Ferlay J et al. Global cancer statistics, 2008. CA Cancer J Clin 2005; 55: 74–108.
3. Larkin G, Eisen T. Renal cell carcinoma and the use of sorafenib. Ther Clin Risk Manag 2006; 2 (1): 87–98.
4. Escudier B, Eisen T, Stadler WM et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356: 125–34.
5. Motzer RJ, Hutson TE, Tomczak P et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356: 115–24.
6. Hudes G, Garducci M, Tomczak P et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007; 356: 2271–81.
7. Escudier B, Pluzanska A, Koralewski P et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: A randomised, double-blind phase III trial. Lancet 2007; 370: 2103–11.
8. Motzer RJ, Escudier B, Oudard S et al. Efficacy of everolimus in advanced renal-cell carcinoma: A randomised, double-blind, placebo-controlled phase III trial. Lancet 2008; 372: 449–56.
9. Frank I, Blute ML, Leibovich BC et al. Independent validation of the 2002 American Joint Committee on cancer primary tumor classification for renal-cell carcinoma using a large, single institution cohort. J Urol 2005; 173: 1889–92.
10. Thomas AA, Rini BI, Lane BR et al. Response of the primary tumor to neoadjuvant sunitinib in patients with advanced renal-cell carcinoma. J Urol 2009; 181: 518–23.
11. Mickisch GH, Garin A, van Poppel H et al. Radical nephrectomy plus interferon- alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: A randomised trial. Lancet 2001; 358: 966–70.
12. Flanigan RC, Salmon SE, Blumenstein BA et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 2001; 345: 1655–9.
13. Atzopodien J, Schmitt E, Gertenbach U et al. Adjuvant treatment with interleukin-2 and interferon-alfa2a-based chemoimmunotherapy in renal cell carcinoma post tumor nephrectomy: Results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). Br J Cancer 2005; 92: 843–6.
14. Clark JI, Atkins MB, Urba WJ et al. Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: A cytokine working group randomised trial. J Clin Oncol 2003; 21: 3133–40.
15. Pizzocaro G, Piva L, Colavita M et al. Interferon adjuvant to radical nephrectomy in Robson stages II and III renal cell carcinoma: A multicentric randomized study. J Clin Oncol 2001; 19: 425–31.
16. Messing EM, Manola J, Wilding G et al. Phase III study of interferon alfa-NL as adjuvant treatment for resectable renal cell carcinoma: An Eastern Cooperative Oncology Group/Intergroup trial. J Clin Oncol 2003; 21: 1214–22.
17. Jonasch E, Wood CG, Matin SF et al. Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma. J Clin Oncol 2009; 27: 4076–81.
18. Cowey L, Amin C, Pruthi R et al. Neoadjuvant clinical trial with sorafenib for patients with stage II or higher renal cell carcinoma. J Clin Oncol.
19. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors: European Organisation for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205–16.
20. Cowey CL, Fielding J, Rathmell WK. The loss of radiographic enhancement in primary renal cell carcinoma tumors following multi-targeted receptor tyrosine kinase therapy is an additional indicator of response. Urology (in press).
21. Amin C, Wallen E, Pruthi RS et al. Preoperative tyrosine kinase inhibition as an adjunct to debulking nephrectomy. Urology 2008; 72: 864–8.
22. Margulis V, Matin SF, Tannir N et al. Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma. J Urol 2008; 180: 94–8.
23. Shuch B, Riggs SB, La Rochelle JC et al. Neoadjuvant targeted therapy and advanced kidney cancer: Observations and implications for a new treatment paradigm. BJU Int 2008; 102: 692–6.
24. Karakiewicz PI, Suardy N, Jeldres C et al. Neoadjuvant sutent induction therapy may effectively down-stage renal cell carcinoma atrial thrombi. Eur Urol 2008; 53: 845–8.
25. Robert G, Gabbay G, Bram R et al. Complete histologic remission after sunitinib neoadjuvant therapy in T3b renal cell carcinoma. Eur Urol 2009; 55: 1477–80.
26. Bex A, van der Veldt AA, Blank C et al: Neoadjuvant sunitinib for surgically complex advanced renal cell cancer of doubtful respectability: Initial experience with downsizing to reconsider cytoreductive surgery. World J Urol 2009; 27: 533–9.

И.В.Поддубная, И.Н.Огнерубова

Кафедра онкологии ГОУ ДПО РМАПО, Москва